ELEVATED SERUM LEVEL OF INTERLEUKIN-10 IN ADULT NEWLY DIAGNOSED NON-HODGKINS‘S LYMPHOMA
Keywords:
Cytokines, IL-10, Non-Hodgkin's lymphomaAbstract
Non-Hodgkin’s lymphoma (NHL) is a group of lymphoproliferative malignant disorders with heterogeneous histological and clinical characteristics. Non-Hodgkin’s lymphoma is characterized by abnormal proliferation or accumulation of B or T lymphocytes. Cytokines are low-molecular-weight proteins with a wide variety of functions. They are involved in the regulation of both the immune and inflammatory response and also play significant roles in the pathogenesis of lymphoma. Aims: We aimed to investigate serum levels of Interleukin -10 in newly diagnosed non-Hodgkin's lymphoma (NHL) patients and their relationship with clinicopathological characteristics and prognostic parameters. Methods: Serum level of IL-10 was measured by enzyme-linked immunosorbent assay in 60 patients with pathologically verified NHL before chemotherapy, and in 20 healthy controls. Results: A total of 60 patients with NHL, 32 men and 28 women. 24 were with Diffuse large B-cell lymphoma (DLBCL), 8 with Mantel cell lymphoma( MCL), 2 with Peripheral T-cell lymphoma (PTCL), 9 with Marginal zone lymphoma (MZL), 10 with Follicular lymphoma( FL), 1 patient with Plasmoablastic lymphoma(PBL) and 6 with Small-cell lymphoma( SCL)..There was significant differences in the serum IL-10 between NHL patients and controls ( p<0.001 ). Serum IL-10 levels were significantly different in the group of patients with aggressive NHL compared with the group of patients with inolent NHL (respectively p= 0.016). Also, serum IL-10 levels were elevated in the group of patients with high level LDH (p= 0.015) compared with the group of patients with a normal level. Multivariate analysis showed a significant difference between the two study groups in terms of IPI (p = 0.005), with a moderate correlation between the type of lymphoma and the risk profile of patients (r = 0.399; p = 0.002). In the group of patients with intermediate and high risk and elevated IL-10 levels have an unfavorable prognosis and short overall survival. Conclusion: Elevated levels of IL-10 are associated with increased tumor growth with poor prognosis and overall survival. Our data suggest that higher serum IL-10 levels could be an independent negative prognostic factor and correlates to poor survival
References
Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J , Favrot M C, (1993). Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82: 2169-2174.
Brocker C, Thompson D, Matsumoto A, Nebert D, Vasiliou V. (2010). Evolutionary divergence and functions of the human interleukin (IL) gene family, Human Genomics 5 (1) 30-55.
Contasta I, Pellegrini P, Berghella AM, Adorno D, ( 2001).Cancer Biother Radiopharmaceut, 16, 63-71
Commins S, Steinke JW, Borish L, (2008). The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28,and IL-29. J Allergy Clin Immunol ;121:1108-1111
Culig Z, Steiner H, Bartsch G, Hobisch A, (2005), J Cell Biochem., 95, 497-505
Del Prete G, De Carli M, Almerigogna F, Giudizi MG,Biagiotti R, Romagnani S (1993). Human IL-10 is produced byboth type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation andcytokine production. J Immunol;150:353-360
Fiorentino DF, Bond MW, Mosmann TR,(1989). Two types of mouse helper T cells, TH2 secretes a factor that inhibits cytokine production by THI clones. J.Exp. Med 170:2081
Guney N, Soydinc HO, Basaran M, Bavbek S, Derin D, Camlica H, Yasasever V, Topuz E, (2009). Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev;10:669-674
Kozowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ, (2003). Concentration of interleukin-6 (IL-6), interleukin-8(IL8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48: 82-84
Lech-Maranda E, Bienvenu J, Michallet AS, Houot R, Robak T, Coiffier B, Salles G, (2006). Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw;17:60-66.
Li N, Grivennikov SI, Karin M (2011). The unholy trinity: inflammation, cytokines, and STAT 3 shape the cancer microenvironment. Cancer Cell;19(4):429-431.[PMC free article] [PubMed]
Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N, (2008). Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol;30:230-239.
Howard M, O'Garra A, (1992). Biological properties of IL-10 . Immunol Today 13:198,
Mocellin S, Marincola FM, Young HA, (2005). Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78: 1043-1051
Moore KW, de Waal MR, Coffman RL and O'Garra A, (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 19:683–765
Mosser DM and Zhang X, (2008). Interleukin-10: New perspectives on an old cytokine Immunol Rev. 226:205–218. ,Pubmed
Ohshima K, Haraoka S, Suzumiya J, Kawasaki C, Kanda M, Kikuchi K, (2000). Leuk Lymphoma, 38 (5-6), 541-545
Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O,Yavuz M N ,Yavuz A, (2004) The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL). J Exp Clin Cancer Res 23: 485-488
Roncarolo MG, Battaglia M, Gregori S (2003). The role of interleukin 10 in the control of autoimmunity. J Autoimmun ;20:269-272
